Prostate News and Research

RSS

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Health Discovery Corporation announced today that it delivered a letter of gratitude and support to Congressman Edolphus Towns, Chairman of the House Committee on Oversight and Government Reform for holding today, March 4, 2010, a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment.”

5 Mar 2010

Heartburn drug Kapidex to be marketed under new name Dexilant

The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant.

4 Mar 2010

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

Testimony emphasizes that health reform bills eliminate prostate cancer screening

The House Committee on Oversight and Government Reform, chaired by Congressman Edolphus Towns, will hold a hearing entitled: "Prostate Cancer: New Questions About Screening and Treatment."

4 Mar 2010

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Researchers in the US and Denmark have made a breakthrough in image-guided targeting of prostate tumors during arc radiotherapy treatments. In research partially supported by Varian Medical Systems, physicists at Stanford University (California, USA) and Aarhus University Hospital (Aarhus, Denmark) have devised a method for 'real-time' tracking of the prostate motion using Varian's On-Board Imager® that shows promise in paving the way for advanced clinical treatments.

4 Mar 2010

Prostate cancer screening: Another set of new guidelines adds to the confusion

Members of America's Prostate Cancer Organizations are concerned that the issuance this morning of yet another set of new guidelines on screening for prostate cancer is only adding to the confusion most men already feel about whether they should or shouldn't be tested for the most common form of cancer in American men.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

The American Urological Association Foundation joins the AUA in its response to the American Cancer Society updated prostate cancer screening guidelines highlighting the importance of shared decision-making between patients and physicians.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Lotus Pharmaceuticals adds five new prescription drugs to its products

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that it had added five new prescription drugs to its products delivered through its national sales channels.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

Study shows cryoablation technique offers a potential treatment for breast cancer

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

3 Mar 2010

Generic version of Flomax Capsules receives FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination.

2 Mar 2010

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

The next treatment for cancer might come from fish says a new research report published in the March 2010 print edition of the FASEB Journal (http://www.fasebj.org). In the report, scientists show that the omega-3 fatty acid, "docosahexaenoic acid" or "DHA," and its derivatives in the body kill neuroblastoma cancer cells.

2 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC.

2 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

ProUroScan prostate imaging system 510(k) application: Inclement weather delays FDA processing

ProUroCare Medical, Inc., a provider of proprietary medical imaging products, indicates that the Food and Drug Administration has informed the industry that the processing of 510(k) applications, which includes the ProUroScan™ prostate imaging system, has been delayed because of the inclement weather in February that impacted the Washington, D.C. area.

26 Feb 2010

Prostate News and Research

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Heartburn drug Kapidex to be marketed under new name Dexilant

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

Testimony emphasizes that health reform bills eliminate prostate cancer screening

Arc radiotherapy treatments: Breakthrough in image-guided targeting of prostate tumors

Prostate cancer screening: Another set of new guidelines adds to the confusion

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

Allergan celebrates 20th anniversary of BOTOX in Canada

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Lotus Pharmaceuticals adds five new prescription drugs to its products

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Study shows cryoablation technique offers a potential treatment for breast cancer

Generic version of Flomax Capsules receives FDA approval

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

ProUroScan prostate imaging system 510(k) application: Inclement weather delays FDA processing

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News